Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.

@article{Gray2009IndependentRO,
  title={Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.},
  author={Robert J. Gray and Suman Bhattacharya and Christopher Bowden and Kathy D. Miller and Robert L. Comis},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 30},
  pages={
          4966-72
        }
}
PURPOSE E2100, an open-label, randomized, phase III trial conducted by the Eastern Cooperative Oncology Group (ECOG), demonstrated a significant improvement in progression-free survival (PFS) and overall response rate (ORR) with paclitaxel plus bevacizumab compared with paclitaxel alone as initial chemotherapy for patients with HER2-negative metastatic breast cancer. METHODS An independent, blinded review of radiologic and clinical data was performed, assessing progression and response… CONTINUE READING
Highly Cited
This paper has 167 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 130 citations

168 Citations

02040'10'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 168 citations based on the available data.

See our FAQ for additional information.